Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexis Vazquez

Pulmonary Disease Jacksonville Beach, FL Doctor of Osteopathy

NPI 1518909167 CMS profile 205151

1361 13Th Ave S Ste 245, Jacksonville Beach, FL 32250

Open in the dashboard

General payments

$18,343

876 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexis Vazquez of Jacksonville Beach, FL is reported in the CMS Open Payments database as having received $18,343 across 876 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,063 126
2024 General $3,016 116
2023 General $2,619 132
2022 General $3,211 134
2021 General $2,376 128
2020 General $1,717 100
2019 General $2,342 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexis Vazquez
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Alexis Vazquez were reported at $3,063. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Alexis Vazquez Pulmonary Disease median Middle half National median
2019 $2,342 $377 $109–$1,340 $163
2020 $1,717 $230 $56–$907 $114
2021 $2,376 $269 $68–$1,072 $132
2022 $3,211 $390 $100–$1,457 $149
2023 $2,619 $419 $114–$1,659 $160
2024 $3,016 $476 $123–$1,818 $164
2025 $3,063 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,450 166 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $2,110 127 payments
  3. Regeneron Healthcare Solutions, Inc. $1,388 54 payments
  4. Genzyme Corporation $1,141 43 payments
  5. Grifols USA, LLC $1,095 51 payments
  6. GlaxoSmithKline, LLC. $820 56 payments
  7. Actelion Pharmaceuticals US, Inc. $814 28 payments
  8. Amgen Inc. $701 31 payments
  9. Insmed, Inc. $683 35 payments
  10. Baxter Healthcare $628 22 payments
  11. Other $5,513 263 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,130 873 payments
  2. Education $212 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $1,145 47 payments
  2. OFEV $1,107 78 payments
  3. DUPIXENT Immunology $1,026 37 payments
  4. BREZTRI $942 42 payments
  5. Prolastin-C Liquid $938 43 payments
  6. FASENRA $877 42 payments
  7. TEZSPIRE Inflammation $665 29 payments
  8. Arikayce $664 34 payments
  9. OPSUMIT $640 22 payments
  10. TEZSPIRE Respiratory $615 23 payments
  11. Other $11,910 566 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

6,679

Median for Pulmonary Disease: 936

Drug cost

$1,860,859

Median for Pulmonary Disease: $487,987

Branded share of claims

52.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 565 $440,856
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 478 $375,582
Ofev Nintedanib Esylate Brand 17 $156,403
Dupixent Pen Dupilumab Brand 36 $131,718
Tezspire Tezepelumab-Ekko Brand 26 $108,576
Dupixent Syringe Dupilumab Brand 24 $96,745
Symbicort Budesonide/Formoterol Fumarate Brand 318 $87,323
Breo Ellipta Fluticasone/Vilanterol Brand 162 $80,808
Spiriva Respimat Tiotropium Bromide Brand 79 $55,181
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 77 $46,830

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$743,680

Of which drugs: $812

Medicare patients

1,382

Average age 76

Services billed

20,798

805 women, 577 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 75%
Diabetes 63%
Arthritis 61%
Ischemic heart disease 55%
Depression 51%
Heart failure 43%
Chronic kidney disease 42%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 40 1,902 $437
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 25 74 $323
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 82 $42
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 72 259 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $408
  • Regeneron Healthcare Solutions, Inc. $341
$748 60 —
TEZSPIRE
  • Amgen Inc. $236
  • AstraZeneca Pharmaceuticals LP $226
$462 26 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $234
$234 17 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $155
$155 11 —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $145
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

876 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record